Navigation Links
Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
Date:5/14/2009

tions that may predispose them to infection.

Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating CIMZIA and periodically during therapy. Patients should be closely monitored for the development of signs and symptoms of infections during and after treatment with CIMZIA, including development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. CIMZIA should be discontinued if a patient develops a serious infection or sepsis. Patients who develop a new infection during treatment with CIMZIA should be closely monitored, undergo a prompt and complete diagnostic workup appropriate for immunocompromised patients, and appropriate antimicrobial therapy should be initiated. Appropriate empiric antifungal therapy should also be considered while a diagnostic workup is performed for patients who develop a serious systemic illness and reside or travel in regions where mycoses are endemic.

During controlled and open-labeled portions of CIMZIA studies of Crohn's disease and other diseases, malignancies (excluding non-melanoma skin cancer) were observed at a rate (95% confidence interval) of 0.5 (0.4, 0.7) per 100 patient-years among 4,650 CIMZIA-treated patients versus a rate of 0.6 (0.2, 1.7) per 100 patient-years among 1,319 placebo-treated patients. The size of the control group and limited duration of the controlled portions of the studies preclude the ability to draw firm conclusions. In studies of CIMZIA for Crohn's disease and other investigational uses, there was one case of lymphoma among 2,657 CIMZIA-treated patients and one case of Hodgkin lymphoma among 1,319 placebo-treated patients. In CIMZIA RA clinical trials (placebo-controlled and open label) a total of three cases of lymphoma were observed among 2,367 patients. This is approximately 2-fold higher than expected in the general population. Patients with
'/>"/>

SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
3. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
6. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
7. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
8. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
9. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
10. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
11. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... CHESTERBROOK, Pa., Oct. 30, 2014   Auxilium ... a fully integrated specialty biopharmaceutical company, today announced ... 30, 2014. The Company highlighted important corporate, commercial, ... "We are very pleased with ... core growth products in our portfolio this quarter, ...
(Date:10/30/2014)... 2014 , Extensively hydrolyzed milk ...   Cow milk protein allergy (CMPA) is the leading cause ... now, it has been managed by eliminating milk proteins ... that it is possible to help build of oral ... children during the first year of life by using ...
(Date:10/30/2014)... 2014 nebulizer is a medical device used ... cystic fibrosis) that converts liquid medication into mist or ... lungs of a patient when inhaled through the mouth ... dominated by various devices powered by electric current and ... COPD and cystic fibrosis and growing number of geriatric ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 3Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 4Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 5Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 6Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 7Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 8Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 9Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 10Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 11Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 12Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 13Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 14Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 15Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 16Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 17Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 18Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 19Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 20Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 21Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 22Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3
... 12, 2007 /PRNewswire-FirstCall/ --,InB:Biotechnologies, Inc. ("BioTech"), a ... announced strong positive,results in studies of vaccines ... novel, proprietary AIPwLV(TM) vaccine technology. The,studies were ... Molecular,Biotechnology (CMB), the Contract Research Organization led ...
... LUND, Sweden, March 13, 2007--Active Biotech AB,(Stockholm:ACTI.ST) ... a first human micro-dosing trial of an,I-3D ... was to determine the pharmacokinetic,characteristics of the ... healthy volunteers. , The study demonstrated that ...
Cached Medicine Technology:Integrated Biopharma's Proprietary Vaccine Technology Achieves,Strong Positive Results 2Active Biotech's I-3D Micro-dosing Clinical Trial Concluded 2
(Date:10/30/2014)... October 30, 2014 Sound Telecom, a leader ... that will assist people any time they wonder, “Should I ... right answer by leading them through a series of yes ... their initial query. , There are many considerations and scenarios ... use an answering service . This decision infographic serves ...
(Date:10/30/2014)... HealthDay Reporter WEDNESDAY, Oct. ... chemical during pregnancy may have effects on genital development in ... baby boys born to moms with greater exposure to a ... -- the space between the genitals and anus. Anogenital distance ... of exposure to androgens ("male" hormones) during pregnancy. The ...
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- Eating a low-carb, high-fat ... treat, according to new research. A review ... Atkins diet, that focuses on foods like bacon, eggs, ... reduce seizures in adults whose condition doesn,t improve with ... percent of people with epilepsy whose seizures are not ...
(Date:10/30/2014)... care respects the fact that a patient,s body ... treatment. Over a third of cancer patients experience ... their conditions. And, increasingly, care providers are exploring ... navigate mental health challenges. A University of Colorado ... Psycho-Oncology asks an important question: after ...
(Date:10/29/2014)... October 29, 2014 – Many of the women at first ... most conveyed to researchers why they had not used the ... large HIV prevention trial that, as a likely consequence, did ... to be effective. , The women were among 127 ... called VOICE D, agreed to take part in in-depth interviews ...
Breaking Medicine News(10 mins):Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3Health News:Decades of research: Effectiveness of phone counseling for cancer patients still unknown 2Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 2Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 3
... San Francisco, Calif., June 07, 2008 Results ... were announced today at the American Diabetes Association ... & Development Center, Inc. Alogliptin, which has ... of dipeptidyl peptidase-4 (DPP-4), is currently under investigation ...
... of,Labor & Industry invites the public to learn more about ... Safety Day from 10 a.m. to 2,p.m. on Wednesday, June ... event will feature an array of interactive services promoting,health and ... can,receive - free of charge - relaxing massages; a cool ...
... they had dropped off at wheel, with 2.2% reporting accidents ... while suffering from a lack of sleep may be a ... , Interviews with 263 students at the University of North ... driving, and 2.2 percent of that group reported having accidents ...
... Physicians (ACP) today pledged its support for enactment of ... Providers Act of 2008. , "The College is able ... incorporates three of our top legislative priorities," ACP President ... (D-MT), chairman of the Senate Finance Committee. , Writing ...
... the nation,s leading,supplier of replacement medical repair parts ... Edge" award for Northern Ohio. The,Entrepreneurs EDGE is ... companies in Northeast Ohio grow their value, while,building ... The,Leading EDGE Award measures, tracks and recognizes companies ...
... AJMC, findings reveal only a handful of measures ... inform health care payers,purchasers, providers and policy makers ... collection methods for physician quality measurement,efforts, Bridges to ... financial impact that results when physicians meet certain ...
Cached Medicine News:Health News:Phase 3 results for alogliptin 2Health News:Phase 3 results for alogliptin 3Health News:Sleepy Driving Prevalent Among Collegians 2Health News:ACP pledges support for Medicare improvements for Patients and Providers Act of 2008 2Health News:Bridges to Excellence Study Assesses Clinical and Financial Impact of Physician Quality Measures 2
... providers can code the charge while completing a ... while away from office, both directly feeding the ... an Encounter Form/Superbill, data entry can be done ... patient payments are posted by reflecting open item ...
... G-3 goniofundus lens incorporate 3 mirrors angled at ... ideal for anterior chamber as well as central ... retinal viewing mirrors are accurately angled and spaced ... fundus. The central portion of the lens ...
The Mid Field 30° lens has a bi-concave design to provide a wider field of view with a 30 degree offset image....
... The Chalam 30° Prism are ... and are recommended for tractional ... and Rhegmatogenus retinal detachment. They ... photocoagulation and other midperipheral laser ...
Medicine Products: